CN111803717A - Preparation method and process of endomucosal injection swelling agent - Google Patents
Preparation method and process of endomucosal injection swelling agent Download PDFInfo
- Publication number
- CN111803717A CN111803717A CN202010532782.9A CN202010532782A CN111803717A CN 111803717 A CN111803717 A CN 111803717A CN 202010532782 A CN202010532782 A CN 202010532782A CN 111803717 A CN111803717 A CN 111803717A
- Authority
- CN
- China
- Prior art keywords
- sodium hyaluronate
- cross
- agent
- solution
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 53
- 239000007924 injection Substances 0.000 title claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 35
- 230000008961 swelling Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 230000008569 process Effects 0.000 title abstract description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 82
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 82
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 82
- 239000000243 solution Substances 0.000 claims abstract description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 238000003756 stirring Methods 0.000 claims abstract description 27
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 22
- 230000001954 sterilising effect Effects 0.000 claims abstract description 18
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 17
- 239000003086 colorant Substances 0.000 claims abstract description 15
- 238000007865 diluting Methods 0.000 claims abstract description 15
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000004132 cross linking Methods 0.000 claims abstract description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 210000004876 tela submucosa Anatomy 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 150000001718 carbodiimides Chemical group 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical group [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims description 2
- 229960000633 dextran sulfate Drugs 0.000 claims description 2
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical group [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 claims description 2
- 229960003988 indigo carmine Drugs 0.000 claims description 2
- 235000012738 indigotine Nutrition 0.000 claims description 2
- 239000004179 indigotine Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000975 dye Substances 0.000 abstract 3
- 239000000499 gel Substances 0.000 description 37
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 15
- 229940014041 hyaluronate Drugs 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 11
- 229960000907 methylthioninium chloride Drugs 0.000 description 11
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 238000012323 Endoscopic submucosal dissection Methods 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 230000002522 swelling effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XBWVGDOUANLQHM-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;propane-1,2,3-triol Chemical compound OCC(O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO XBWVGDOUANLQHM-BAOOBMCLSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 238000012277 endoscopic treatment Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a preparation method and a process for injecting a swelling agent under an endoscope mucosa. The dyeing agent is composed of cross-linked sodium hyaluronate and a dyeing agent, wherein the mass content of the cross-linked sodium hyaluronate is 0.1-0.8%, and the mass content of the dyeing agent is 0.0005-0.05%; the preparation process comprises adding sodium hyaluronate aqueous solution into sodium hydroxide solution, stirring to thin, adding cross-linking agent 1, 4-butanediol diglycidyl ether (BDDE), and performing cross-linking reaction; and after the crosslinking is finished, adjusting the pH value by using a hydrochloric acid solution, diluting by using a phosphate buffer solution containing a coloring agent, homogenizing, and performing moist heat sterilization to obtain the endoscopic submucosal injection swelling agent. The swelling agent prepared according to the invention has the advantages of less raw material consumption, small injection pressure, high swelling height, long maintaining time, terminal sterilization, easy production, transportation and storage and higher safety.
Description
Technical Field
The invention relates to a preparation method and a process for injecting a swelling agent under an endoscope mucosa. The endoscopic submucosa injection swelling agent is a gel prepared from cross-linked polysaccharide, a coloring agent and a phosphate buffer solution, and can be used as a material for submucosal injection of the digestive tract.
Background
The digestive tract tumor accounts for more than half of the total malignant tumor in China, the early diagnosis and early treatment of the digestive tract tumor are the key points for improving the curative effect, and the digestive tract early cancer is treated by an endoscope, so that the survival rate in 5 years can be greatly improved to more than 90 percent, and the endoscope has the advantages of small wound, short hospitalization time, low cost and the like, thereby having an important role in diagnosing and treating the digestive tract early cancer and precancerous lesion.
In recent years, endoscopic techniques, such as endoscopic submucosal resection (EMR) and Endoscopic Submucosal Dissection (ESD), have revolutionized the diagnosis and treatment of digestive tract diseases and become the first treatment for early cancers and precancerous lesions of the digestive tract, and thus endoscopic submucosal injection of a swelling agent is particularly important in digestive endoscopic surgery. By injecting the submucosal swelling agent, the target mucosa can be swelled to facilitate excision, complications such as bleeding and perforation can be reduced, and whether endoscopic treatment can be performed can be preliminarily determined. Compared with EMR, the ESD excision range is larger, the operation time is correspondingly prolonged, the probability of complications in the treatment process is correspondingly increased due to the fact that the excision focus is larger, and effective submucosal injection is the decisive factor for ensuring ESD safety. Therefore, with the development of endoscopic technology, finding an ideal submucosal injection has become one of the targets that researchers and endoscopists have explored.
Sodium Hyaluronate (HA), a linear polysaccharide composed of double-bond repeating structural units formed by connecting D-glucuronic acid and N-acetyl-D-glucosamine through alternate (1 → 4) and (1 → 3) glycosidic bonds, is used as a human endogenous substance and is widely used for injection in multiple departments such as ophthalmology, orthopedics, plastic cosmetology and the like. Sodium hyaluronate has high viscosity and water absorption, and is not easy to be absorbed quickly after injection, so the swelling effect is superior to that of common clinical physiological saline, 50% glucose solution, hypertonic saline and concentrated glycerol-fructose solution.
Chinese patents CN105561402A and CN 105287626a disclose methods of using a non-crosslinked sodium hyaluronate solution as a submucosal injection for endoscopes, respectively, the swelling effect is significantly better than that of normal saline, and sodium hyaluronate with excellent lubricating effect has physiological functions of promoting angiogenesis, promoting wound healing, resisting tumor, regulating immunity, and the like.
CN107456612A also discloses a submucosal injection solution and the like. However, the sodium hyaluronate solution is not stable, has strict requirements on sterilization mode and storage conditions, needs to be produced by an aseptic processing method, and increases the difficulty for production, processing, transportation and storage of products. Because the cost of the sodium hyaluronate is higher, the reduction of the dosage of the sodium hyaluronate in the product is particularly critical.
Disclosure of Invention
The invention aims to provide a preparation method and a process of an endoscopic submucosal injection swelling agent, which can solve the technical problems. .
The endoscopic submucosa injection swelling agent provided by the invention is composed of cross-linked sodium hyaluronate and a coloring agent, wherein the mass percentage concentration of the cross-linked sodium hyaluronate is 0.1-0.8%, and the mass percentage concentration of the coloring agent is 0.0005-0.05%; the preparation process comprises adding sodium hyaluronate aqueous solution into sodium hydroxide solution, stirring to thin, adding cross-linking agent 1, 4-butanediol diglycidyl ether (BDDE), and performing cross-linking reaction; and after the crosslinking is finished, adjusting the pH value by using a hydrochloric acid solution, diluting by using a phosphate buffer solution containing a coloring agent, homogenizing, and performing moist heat sterilization to obtain the endoscopic submucosal injection swelling agent.
The mass ratio of the cross-linking agent to the sodium hyaluronate is as follows: 0.001-0.1: 1.
The cross-linking agent can be replaced by carbodiimide cross-linking agent, sulfone cross-linking agent, aldehyde cross-linking agent and other epoxy cross-linking agent.
The coloring agent can be replaced by indigo carmine and Congo red.
The molecular weight range of the sodium hyaluronate is 20-2000 kDa, and the preferred molecular weight range is 150-1500 kDa.
The sodium hyaluronate can be prepared from the following polysaccharides: sodium alginate, cellulose and its derivatives, starch, dextran, and chondroitin sulfate.
The preparation method of the endomucosal injection swelling agent provided by the invention comprises the following steps:
1) dissolving sodium hyaluronate in water according to a certain amount to prepare an aqueous solution, and standing and dissolving for 2-10 hours at the temperature of 10-30 ℃. The mass percentage concentration of the sodium hyaluronate is 0.5-50%.
2) Sodium hydroxide solution was added to the aqueous solution and stirred to thin the sodium hyaluronate aqueous solution. The mass percentage concentration of the sodium hydroxide solution is 2-20%.
3) And adding a cross-linking agent into the diluted sodium hyaluronate aqueous solution, and stirring for reaction at the reaction temperature of 10-50 ℃ for 18-24 hours. The mass ratio of the cross-linking agent to the sodium hyaluronate is as follows: 0.001-0.1: 1.
4) Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing a coloring agent to prepare a cross-linked gel with the mass percent of 0.1-0.8%. The mass percentage concentration of the coloring agent is 0.0005% -0.05%.
5) And (3) homogenizing the cross-linked gel, and sterilizing at the temperature of 121 +/-1 ℃ for 5-15 min to obtain the endoscopic submucosal injection swelling agent.
The invention provides a preparation method and a process for an endoscopic submucosal injection swelling agent, which solve the problems in the prior art, adopts a chemical method to crosslink polysaccharide, and adds a coloring agent to obtain an endoscopic submucosal injection swelling agent gel.
The invention has the outstanding characteristics that after the polysaccharide is crosslinked to form gel, all molecules inside the gel are connected to form a net-shaped bracket, and based on the three-dimensional space grid, a large amount of water can be combined, so that the gel with extremely low concentration can achieve a better swelling effect, and the low concentration can reduce the consumption of raw materials and simultaneously keep lower injection pressure. Compared with the non-crosslinked sodium hyaluronate solution, the dosage of the raw materials can be reduced by more than 50%, the injection pressure can be reduced by more than 20%, and the bulge height after 60min can be improved by more than 14%.
Drawings
FIG. 1 is a graph showing the effect of comparative experiments on the elevation height at the initial time of injecting the present invention under the gastric mucosa of a rabbit; comparative example A: HA molecular weight is 825kD, concentration is 0.4%; example 4: the molecular weight of HA is 1270kD, the mass ratio of the cross-linking agent to the HA is 0.005:1, and the concentration is 0.4%; example 7: the molecular weight of HA is 825kD, the mass ratio of the cross-linking agent to the HA is 0.0075:1, and the concentration is 0.2%; example 9: the molecular weight of HA is 1270kD, the mass ratio of the cross-linking agent to HA is 0.0075:1, and the concentration is 0.2%).
FIG. 2 is a graph showing the effect of comparative experiments on the elevation height of a rabbit injected under the gastric mucosa for 60 min; (control example A: HA molecular weight 825kD at 0.4%; example B4: HA molecular weight 1270kD, crosslinker to HA mass ratio 0.005:1, concentration 0.4%; example C7: HA molecular weight 825kD, crosslinker to HA mass ratio 0.0075:1, concentration 0.2%; example D9: HA molecular weight 1270kD, crosslinker to HA mass ratio 0.0075:1, concentration 0.2%).
Detailed Description
The present invention is further illustrated by the following examples, which do not limit the scope of the present invention.
The experimental methods in the examples, in which specific conditions are not specified, are generally performed under the conditions described in the manual and the conventional conditions, or under the conditions recommended by the manufacturer; the materials, reagents and the like used, unless otherwise specified, are commercially available.
Example 1: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with a molecular weight of 825 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with a mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, and after dilution by stirring, 50. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, and after stirring, the mixture was left at 25 ℃ to continue the reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.4%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 2: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with a molecular weight of 825 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with a mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, followed by dilution with stirring, and 75. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, followed by stirring and standing at 25 ℃ for continuous reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.4%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 3: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with a molecular weight of 825 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with a mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, and after dilution by stirring, 100. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, and after stirring, the mixture was left at 25 ℃ to continue the reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.4%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 4: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with the molecular weight of 1270 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with the mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, and after dilution by stirring, 50. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, and after stirring, the mixture was left at 25 ℃ to continue the reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.4%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 5: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with the molecular weight of 1270 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with the mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, followed by dilution with stirring, and 75. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, followed by stirring and standing at 25 ℃ for continuous reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.4%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 6: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with the molecular weight of 1270 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with the mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, and after dilution by stirring, 100. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, and after stirring, the mixture was left at 25 ℃ to continue the reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.4%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 7: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with a molecular weight of 825 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with a mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, followed by dilution with stirring, and 75. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, followed by stirring and standing at 25 ℃ for continuous reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.2%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 8: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with a molecular weight of 825 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with a mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, and after dilution by stirring, 100. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, and after stirring, the mixture was left at 25 ℃ to continue the reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.2%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 9: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with the molecular weight of 1270 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with the mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, followed by dilution with stirring, and 75. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, followed by stirring and standing at 25 ℃ for continuous reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.2%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Example 10: preparation of Cross-Linked sodium hyaluronate gels
10g of sodium hyaluronate powder (with the molecular weight of 1270 kDa) is weighed and dissolved in 40mL of water to obtain a sodium hyaluronate solution with the mass percentage of 25%. 5mL of 20% sodium hydroxide solution was added, and after dilution by stirring, 100. mu.L of 1, 4-butanediol diglycidyl ether (BDDE) was added to the solution, and after stirring, the mixture was left at 25 ℃ to continue the reaction for 24 hours. Firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing 0.001% of methylene blue to prepare the crosslinked sodium hyaluronate gel with the mass percentage of 0.2%. Homogenizing the gel, and sterilizing at 121 + -1 deg.C for 15min to obtain the intra-mucosal injection swelling agent.
Comparative example: preparation of sodium hyaluronate solution
Weighing 4g of sodium hyaluronate powder (with the molecular weight of 825 kDa), dissolving the sodium hyaluronate powder in 100mL of phosphate buffer solution containing 0.001% of methylene blue, and stirring the solution until the sodium hyaluronate powder is completely dissolved to prepare 0.4% of sodium hyaluronate solution in percentage by mass. Then, the mixture was filtered and sterilized to obtain an endoscopic submucosal injection swelling agent as a control example.
Example 11: bump height comparative experiment 1
The injections of each example and comparative example were filled in 2.25ml prefilled syringes, and the pushing force and the compression resistance were measured. Detecting the extrusion force at the speed of 30mm/min by using a UTM6202 electronic universal tensile testing machine of Shenzhen Sansi longitudinal and transverse science and technology Limited, wherein the used extrusion needle is a 27 Gx 1/2 model needle of TSK company; the axial force test is carried out by using a DHR-2 rheometer of TA company under the conditions of the temperature of 37 ℃ and the pressing force of 0.5N, and the average value of the axial force within 150-180 s is calculated to be used as the detection of the compression resistance. As shown in table 1, the extrusion forces of examples 4, 7, 8, and 9 are all smaller than those of the comparative examples, i.e., the injection pressure during actual use is smaller, and the injection operation is easier, while the axial forces of examples 2, 3, 4, 5, 6, 7, and 9 are all larger than those of the comparative examples, i.e., the compressive capacity is better. In summary, the injection pressures of examples 4, 7 and 9 were all lower than those of the comparative example, and the compressive capacities were all better than those of the comparative example. Therefore, the cross-linked sodium hyaluronate is used as the swelling agent for injection under the mucosa of the endoscope, can be sterilized at the end, is easy to produce, transport and store, is safer, and has small injection pressure and strong pressure resistance.
Table 1:
example 12: bump height comparison experiment
According to the results of table example 11, from the comparison results of the extrusion force, the elastic modulus and the axial force, examples 4, 7 and 9 are superior to the comparative example, so that the comparative experiments of the bump height are further performed by selecting examples 4, 7 and 9 and comparing with the comparative example. Fresh rabbit stomach was cut with a scalpel, laid flat on a foam plate, and 0.5ml of each injection was injected into the stomach submucosa. After the injection is finished, a bulge is formed under the mucous membrane, and the initial time and the height of the bulge of the mucous membrane after 60min are respectively recorded. As shown in table 2, it is understood that the ridge height in the injection time of example 4 is superior but the maintenance ability is slightly inferior to that of the control example, and the ridge height at the initial injection time of example 7 is slightly lower than that of the control example but the maintenance ability is superior, and the ridge height can be maintained after the injection time of 60min (maintenance rate 100%), whereas the initial ridge height (6.1 mm) and the maintenance ability of example 9 are superior to those of the control example (maintenance rate 100%). Overall, example 9 was optimized, example 7 times, and in addition, the amount of sodium hyaluronate used in examples 7 and 9 was only 1/2 for the control.
Therefore, the cross-linked sodium hyaluronate is used as the swelling agent for endoscopic submucosal injection, has the advantages of small injection pressure, good pressure resistance, terminal sterilization, easy production, transportation and storage and higher safety, can maintain a more lasting swelling effect, effectively reduces the using amount of the sodium hyaluronate, greatly reduces the cost, and has important clinical significance and application value.
Table 2:
note: 60min bulge height maintenance =60min bulge height/bulge height at initial time × 100%.
Claims (10)
1. An endoscopic submucosa injection swelling agent comprises cross-linked sodium hyaluronate and a coloring agent, wherein the mass percentage concentration of the cross-linked sodium hyaluronate is 0.1-0.8%, and the mass percentage concentration of the coloring agent is 0.0005-0.05%; the preparation process comprises adding sodium hyaluronate aqueous solution into sodium hydroxide solution, stirring to thin, adding cross-linking agent 1, 4-butanediol diglycidyl ether (BDDE), and performing cross-linking reaction; adjusting the pH value with a hydrochloric acid solution after crosslinking is finished, diluting with a phosphate buffer solution containing a coloring agent, homogenizing, and performing moist heat sterilization to obtain an endoscopic submucosal injection swelling agent; the mass ratio of the cross-linking agent to the sodium hyaluronate is as follows: 0.001-0.1: 1.
2. An endoscopic submucosal injection swelling agent according to claim 1, wherein said sodium hyaluronate has a molecular weight of 20 to 2000kDa, preferably 150 to 1500 kDa.
3. The endoscopic submucosal injection swelling agent according to claim 1, wherein said cross-linking agent is replaced with a carbodiimide-based cross-linking agent, a sulfone-based cross-linking agent, an aldehyde-based cross-linking agent, and other epoxy-based cross-linking agents.
4. The endoscopic submucosal injection bump according to claim 1, wherein said coloring agent is replaced with indigo carmine or congo red.
5. The endomydrical injection bump agent of claim 1, characterized in that the sodium hyaluronate is coated with a polysaccharide: sodium alginate, cellulose and derivatives, starch, dextran, and chondroitin sulfate.
6. The method of claim 1, comprising the steps of:
1) dissolving sodium hyaluronate in water according to a certain amount to prepare an aqueous solution, and standing for 2-10 hours at the temperature of 10-30 ℃;
2) adding sodium hydroxide solution into the aqueous solution, and stirring to dilute the sodium hyaluronate aqueous solution;
3) adding a cross-linking agent into the diluted sodium hyaluronate aqueous solution, and stirring for reaction at the reaction temperature of 10-50 ℃ for 18-24 hours;
4) firstly, adjusting the pH value of a reaction system to 6.0-8.0 by using a hydrochloric acid solution, and then diluting by using a phosphate buffer solution containing a coloring agent to prepare a cross-linked gel with the mass percent of 0.1-0.8%;
5) and (3) homogenizing the cross-linked gel, and sterilizing at the temperature of 121 +/-1 ℃ for 5-15 min to obtain the endoscopic submucosal injection swelling agent.
7. The preparation method according to claim 6, wherein the mass percent concentration of the sodium hyaluronate is 0.5% -50%.
8. The preparation method according to claim 6, wherein the concentration of the sodium hydroxide solution is 2-20% by mass.
9. The preparation method according to claim 6, wherein the mass ratio of the cross-linking agent to the sodium hyaluronate is as follows: 0.001-0.1: 1.
10. The method according to claim 6, wherein the concentration of the coloring agent is 0.0005% to 0.05% by mass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010532782.9A CN111803717A (en) | 2020-06-12 | 2020-06-12 | Preparation method and process of endomucosal injection swelling agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010532782.9A CN111803717A (en) | 2020-06-12 | 2020-06-12 | Preparation method and process of endomucosal injection swelling agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111803717A true CN111803717A (en) | 2020-10-23 |
Family
ID=72845827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010532782.9A Pending CN111803717A (en) | 2020-06-12 | 2020-06-12 | Preparation method and process of endomucosal injection swelling agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111803717A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116063684A (en) * | 2023-04-03 | 2023-05-05 | 中日友好医院(中日友好临床医学研究所) | Injection hydrogel applied to endoscopic submucosal stripping technology and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102226009A (en) * | 2011-06-09 | 2011-10-26 | 西安力邦制药有限公司 | Method for preparing crosslinking hyaluronic acid gel |
| CN102863631A (en) * | 2012-09-29 | 2013-01-09 | 杭州嘉伟生物制品有限公司 | Cross-linked sodium hyaluronate gel for tissue filler for plastic surgery and method for preparing cross-linked sodium hyaluronate gel |
| CN103146003A (en) * | 2013-03-06 | 2013-06-12 | 上海其胜生物制剂有限公司 | Preparation method of low-temperature secondary cross-linked sodium hyaluronate gel |
| US20150005394A1 (en) * | 2004-09-27 | 2015-01-01 | Boston Scientific Scimed, Inc. | Devices and methods and agent-assisted medical procedures |
| CN107456612A (en) * | 2016-06-02 | 2017-12-12 | 山东威高药业股份有限公司 | Submucosal injection solution |
| CN109897203A (en) * | 2017-12-11 | 2019-06-18 | 杭州科腾生物制品有限公司 | A kind of straight line cross-linked-hyaluronic acid preparation method |
| CN111132705A (en) * | 2017-05-29 | 2020-05-08 | Kh医学技术有限责任公司 | Sterile injection composition containing cross-linked hyaluronic acid and articaine |
-
2020
- 2020-06-12 CN CN202010532782.9A patent/CN111803717A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150005394A1 (en) * | 2004-09-27 | 2015-01-01 | Boston Scientific Scimed, Inc. | Devices and methods and agent-assisted medical procedures |
| CN102226009A (en) * | 2011-06-09 | 2011-10-26 | 西安力邦制药有限公司 | Method for preparing crosslinking hyaluronic acid gel |
| CN102863631A (en) * | 2012-09-29 | 2013-01-09 | 杭州嘉伟生物制品有限公司 | Cross-linked sodium hyaluronate gel for tissue filler for plastic surgery and method for preparing cross-linked sodium hyaluronate gel |
| CN103146003A (en) * | 2013-03-06 | 2013-06-12 | 上海其胜生物制剂有限公司 | Preparation method of low-temperature secondary cross-linked sodium hyaluronate gel |
| CN107456612A (en) * | 2016-06-02 | 2017-12-12 | 山东威高药业股份有限公司 | Submucosal injection solution |
| CN111132705A (en) * | 2017-05-29 | 2020-05-08 | Kh医学技术有限责任公司 | Sterile injection composition containing cross-linked hyaluronic acid and articaine |
| CN109897203A (en) * | 2017-12-11 | 2019-06-18 | 杭州科腾生物制品有限公司 | A kind of straight line cross-linked-hyaluronic acid preparation method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116063684A (en) * | 2023-04-03 | 2023-05-05 | 中日友好医院(中日友好临床医学研究所) | Injection hydrogel applied to endoscopic submucosal stripping technology and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK173138B1 (en) | Process for Preparing an Iron Dextran Compound, Iron Dextran Compound Prepared by the Process, Pharmaceutical | |
| TWI639434B (en) | Mucoadhesive compositions comprising hyaluronic acid and chitosan for topical application | |
| CN104874007A (en) | surgical hydrogel | |
| CN111150881A (en) | Medical recombinant collagen spray and preparation method thereof | |
| CN115887742B (en) | Preparation method of antibacterial functional collagen-based injectable self-repairing hydrogel | |
| CN104761734B (en) | A kind of preparation method of amino acid crosslinks hyaluronic acid sodium gel | |
| CN113350567A (en) | Biocompatible polymer dressing based on collagen | |
| CN107854729A (en) | A kind of fibroin albumen base self-healing hydrogel and preparation method thereof | |
| WO2019033596A1 (en) | Method for preparing single-phase modified sodium hyaluronate gel | |
| Liu et al. | Design and validation of performance-oriented injectable chitosan thermosensitive hydrogels for endoscopic submucosal dissection | |
| CN111803717A (en) | Preparation method and process of endomucosal injection swelling agent | |
| CN107029281A (en) | A kind of preparation method of Absorbable hemostatic material | |
| CN105327389A (en) | Collagen aggregate based flocculent antibacterial hemostatic material and preparation method thereof | |
| CN115739031A (en) | Application of chitosan or derivatives thereof in removing endotoxin in gelatin | |
| CN110615838B (en) | Sterile instant undenatured natural collagen freeze-dried product and preparation method thereof | |
| CN116159192B (en) | Injectable hemostatic anti-adhesion hydrogel and preparation method thereof | |
| CN111686664B (en) | Emulsified cross-linked sodium hyaluronate gel microsphere for injection and preparation method thereof | |
| CN107812244B (en) | Preparation of liquid collagen filler | |
| CN107362352B (en) | A kind of protein or polypeptide composition and its preparation method and use | |
| CN106693029A (en) | Preparation method of chitosan oligosaccharide -based polyelectrolyte styptic powder | |
| CN113144277B (en) | Injectable fluid gelatin and preparation method and application thereof | |
| Sun et al. | Self-healing hydrogel prepared from gallic acid coupled P (NIPAM-co-AH) and oxidized sodium alginate for diabetic wound repairing | |
| CN103623413B (en) | Preparation method and application of controlled release carrier material of sucrose ester | |
| CN103446180B (en) | The application of a kind of Bacterial cellulose chitosan plural gel and preparation and interior therapeutic | |
| CN114196047A (en) | Sericin and bagasse xylan bionic composite hydrogel as well as preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201023 |
|
| RJ01 | Rejection of invention patent application after publication |